Group 1: Company Developments - DeguTech (300950) experienced its first "limit down" since its listing, closing with a drop of 7.14 million shares, primarily due to the potential termination of a significant asset restructuring plan [1][3] - On November 6, DeguTech announced it would discuss terminating the major asset restructuring transaction after receiving feedback from Haowei Cloud Computing Technology Co., Ltd., indicating difficulties in meeting the demands of all parties involved [3] Group 2: Market Performance - On November 10, the Shanghai Composite Index closed up 0.53%, surpassing the 4000-point mark, with the consumer sector showing strong performance across various sub-industries, including beauty care, food and beverage, retail, and tourism [4] - The beauty care sector leader, Aimeike, saw an intraday increase of over 8%, closing with a gain of 4.92%. The food and beverage sector also had notable performers, with Huanlejia hitting a "limit up" [4] Group 3: Consumer Sector Analysis - As of November 10, the food and beverage, beauty care, and retail sectors have shown underperformance, with year-to-date index gains of less than 10%, lagging behind the Shanghai Composite Index [6] - The food and beverage industry has been particularly weak, with its index ranking at the bottom among all industry indices, indicating a potential opportunity for investment as the sector approaches a recovery phase [6] Group 4: Low PE Stocks - A total of 123 consumer stocks with rolling P/E ratios below 30 and year-to-date performance lagging behind the Shanghai Composite Index have been identified, including major companies like Kweichow Moutai and Gree Electric [7][8] - Among these, 43 stocks are projected to have over 20% upside potential based on institutional forecasts, with companies like Perla and Xueda Education showing significant expected growth [9][10]

Core Viewpoint - The company, Degute, plans to terminate the acquisition of 100% equity in Haowei Technology due to difficulties in reaching an agreement on key terms of the transaction, which was intended to create a second growth curve for the company [2][4][6]. Group 1: Transaction Details - Degute announced the termination of the major asset restructuring transaction, stating that it could not form a satisfactory plan for all parties involved within the effective time window [2][6]. - The transaction was initially planned to be executed through the issuance of shares and cash payment to acquire Haowei Technology, aiming to expand into telecom software development and services, cloud and AI software development, and industry digital solutions [2][10]. - The company has committed not to plan any major asset restructuring for at least one month following the announcement of the termination [7]. Group 2: Stakeholder Information - Haowei Technology has no controlling shareholder or actual controller, with a total of 14 shareholders. The top three shareholders are Nanjing Xiruang Enterprise Management Partnership (27.83%), ZTE Corporation (27.62%), and Nanjing Jiayuteng Enterprise Management Partnership (13.85%) [7][8]. - The major stakeholders have not reached an agreement on the valuation for the restructuring, performance commitments, and compensation terms [4][6]. Group 3: Financial Performance - Degute's net profits for the years 2022 to 2024 are projected to be 65.58 million, 38.66 million, and 96.72 million yuan respectively, with non-recurring net profits of 57.78 million, 33.63 million, and 93.44 million yuan [10]. - Haowei Technology's net profits for 2023, 2024, and the first quarter of 2025 are expected to be 202 million, 205 million, and -133 million yuan respectively, indicating potential volatility in earnings [15]. Group 4: Industry Context - The industry in which Haowei Technology operates shows seasonal revenue characteristics, primarily serving telecommunications, government, and energy sectors, which typically plan their product or service procurement annually, with acceptance of products generally occurring in the second half of the year [17].

Core Viewpoint - The company Deguot plans to terminate the acquisition of 100% equity in Haowei Technology due to the inability to reach an agreement on key terms of the transaction with the counterparties [1][2]. Group 1: Transaction Details - Deguot intended to acquire Haowei Technology through a combination of share issuance and cash payment, aiming to create a second growth curve for the company [1][4]. - The negotiation process has been ongoing, but Deguot and the counterparties have failed to agree on the transaction price and other core terms [2]. - The major shareholders of Haowei Technology include Nanjing Xiruan Enterprise Management Partnership, ZTE Corporation, and Nanjing Jiayuteng Enterprise Management Partnership, holding 27.83%, 27.62%, and 13.85% respectively [3]. Group 2: Financial Performance - Deguot's net profit for the years 2022 to 2024 is projected to be 65.58 million, 38.66 million, and 96.71 million respectively, with non-recurring net profit figures of 57.76 million, 33.63 million, and 93.44 million [4]. - In the first three quarters of 2025, Deguot's net profit decreased by 26.39% to 72.26 million, while the non-recurring net profit fell by 31.86% to 65.24 million [4]. Group 3: Haowei Technology Overview - Haowei Technology is an international software and information technology service provider, focusing on digital transformation solutions based on cloud computing, big data, and artificial intelligence for telecom operators, government, and enterprise clients [5]. - The company has three main business lines: telecom software development and services, cloud and AI software development and services, and industry digital solutions, with significant advantages in overseas business [5]. - Haowei Technology's net profit for 2023, 2024, and the first quarter of 2025 is projected to be 202 million, 205 million, and -13.3 million respectively [6].

截至月份: 2025年10月31日 狀態: 新提交 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 致：香港交易及結算所有限公司 公司名稱: 李氏大藥廠控股有限公司 呈交日期: 2025年11月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00950 | 說明 | 李氏大藥廠控股有限公司 | | | | | | | | | | 法定/註冊股份數目 | | 面值 | | | | 法定/註冊股本 | | | 上月底結存 | | | 1,000,000,000 HKD | | | 0.05 HKD | | | 50,000,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | | 本月底結存 | | | 1,000,000,000 HKD | | | 0.05 HKD | | | 50,000,0 ...

Core Viewpoint - Lee's Pharmaceutical Holdings Limited (00950) announced the grant of stock options to several qualified participants under the stock option plan adopted on May 19, 2022, with a total of 1.764 million shares available for subscription [1] Summary by Category - **Company Announcement** - The company will grant stock options on October 15, 2025, allowing the subscription of a total of 1.764 million ordinary shares [1]

Core Viewpoint - Lee's Pharmaceutical Holdings Limited (00950) announced the granting of stock options to several qualified participants under the stock option plan adopted on May 19, 2022, allowing the subscription of a total of 1.764 million ordinary shares of the company [1] Group 1 - The stock options were granted on October 15, 2025 [1] - The total number of shares that can be subscribed through the stock options is 1.764 million [1]

Core Viewpoint - Lee's Pharmaceutical Holdings Limited (00950.HK) announced the granting of stock options to several eligible participants under the stock option plan adopted on May 19, 2022, which allows for the subscription of a total of 1.764 million ordinary shares of the company [1] Group 1 - The stock options will be granted on October 15, 2025 [1] - The total number of shares available for subscription through the stock options is 1.764 million [1]

截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 李氏大藥廠控股有限公司 呈交日期: 2025年10月2日 I. 法定/註冊股本變動 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00950 | 說明 | | 李氏大藥廠控股有限公司 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,000,000,000 | HKD | | 0.05 | HKD | | 50,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 1,000,000,000 | HKD | | 0.05 | HKD | | 50,000,00 ...

Lee's Pharmaceutical Holdings Limited 李氏大藥廠控股有限公司 * (incorporated in the Cayman Islands with limited liability) （於開曼群島註冊成立之有限公司） (Stock Code 股份代號: 950) N O T I F I C AT I O N L E T T E R 通 知 信 函 19 September 2025 Dear Non-registered holders, Lee's Pharmaceutical Holdings Limited (the "Company") – Notice of Publication of Interim Report (the "Current Corporate Communication") The Current Corporate Communication of the Company have been published in English and Chinese languages and are available on the websi ...

Lee's Pharmaceutical Holdings Limited 李氏大藥廠控股有限公司 * (incorporated in the Cayman Islands with limited liability) （於開曼群島註冊成立之有限公司） (Stock Code 股份代號: 950) N O T I F I C AT I O N L E T T E R 通 知 信 函 Dear Registered Shareholders, Lee's Pharmaceutical Holdings Limited (the "Company") – Notice of Publication of Interim Report (the "Current Corporate Communication") The Current Corporate Communication of the Company have been published in English and Chinese languages and are available on the website of The Stock E ...